Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda
California
94502
United States
Tel: 650-837-7000
Website: http://www.exelixis.com/
766 articles with Exelixis, Inc.
-
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Exelixis, Inc. reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
-
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May 2022
5/4/2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2022 Healthcare Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 11, 2022 in Las Vegas.
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
5/3/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
-
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
4/26/2022
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
4/14/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114.
-
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
4/13/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.
-
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
3/25/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX®.
-
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
3/14/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC).
-
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March 2022
3/2/2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March.
-
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2/17/2022
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
-
Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).
-
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
2/3/2022
Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT.
-
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
2/2/2022
Exelixis, Inc. announced that company management will participate in a fireside chat at the virtual Guggenheim Healthcare Talks Oncology Day on Wednesday, February 9, 2022 at 1:30pm ET / 10:30am PT.
-
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
1/18/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy.
-
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
1/9/2022
Exelixis, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2021, provided financial guidance for full year 2022, and delivered an update on its business.
-
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
1/6/2022
Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC).
-
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
1/5/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib (CABOMETYX®).
-
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
1/4/2022
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15pm ET / 2:15pm PT.